Skip to main content

Table 3 Incidence rate ratios of 842 breast cancer patients followed by thyroid cancer, stratified by factors

From: Clinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: an analysis of the SEER database

Variable

Total

6–36 months

> 36 months

Observed

SIR

CI low

CI high

Excess risk

Observed

SIR

CI low

CI high

Observed

SIR

CI low

CI high

Race

 White

660

1.15*

1.06

1.24

0.37

263

1.67**

1.47

1.88

397

0.95

0.86

1.05

 Black

77

1.88**

1.48

2.34

1.61

32

2.63**

1.80

3.71

45

1.56*

1.14

2.09

 Asian or Pacific Islander

97

1.46*

1.18

1.78

1.19

43

2.19*

1.59

2.95

54

1.15

0.87

1.51

Site

 Central portion

55

1.48*

1.12

1.93

1.13

28

2.76**

1.84

3.99

27

1.00

0.66

1.45

 Upper-inner

90

1.23

0.99

1.51

0.56

32

1.53*

1.05

2.16

58

1.11

0.84

1.43

 Lower-inner

44

1.20

0.87

1.62

0.49

17

1.64

0.96

2.63

27

1.03

0.68

1.50

 Upper-outer

301

1.19*

1.06

1.33

0.46

112

1.65*

1.36

1.98

189

1.02

0.88

1.18

 Lower-outer

56

1.20

0.91

1.56

0.50

20

1.50

0.92

2.32

36

1.08

0.76

1.50

 Overlapping lesion

167

1.19*

1.02

1.39

0.48

82

2.04**

1.63

2.54

85

0.85

0.68

1.05

Grade

 1

136

1.12

0.94

1.33

0.31

45

1.26

0.92

1.68

91

1.07

0.86

1.31

 2

350

1.27*

1.14

1.41

0.66

134

1.72*

1.44

2.04

216

1.09

0.95

1.25

 3

283

1.30*

1.16

1.47

0.76

135

2.16**

1.81

2.56

148

0.96

0.81

1.12

ER

 Positive

601

1.24*

1.14

1.34

0.59

242

1.71*

1.50

1.94

359

1.04

0.94

1.16

 Negative

155

1.25*

1.06

1.47

0.63

72

2.10**

1.65

2.65

83

0.93

0.74

1.15

PR

 Positive

532

1.27*

1.17

1.39

0.68

216

1.79**

1.56

2.04

316

1.06

0.95

1.19

 Negative

202

1.15

0.99

1.32

0.36

92

1.78**

1.44

2.19

110

0.88

0.71

1.06

ER (+) PR (+)

507

1.26*

1.15

1.37

0.64

206

1.75**

1.52

2.01

301

1.05

0.94

1.18

ER (−) PR (−)

125

1.16

0.96

1.38

0.40

61

1.97*

1.51

2.53

64

0.83

0.64

1.06

  1. SIR Standardized incidence ratio, CI Confidence interval, ER Estrogen receptor, PR Progesterone receptor
  2. *p < 0.05; **p < 0.01